|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2005-11-7
|
|
pubmed:abstractText |
Bortezomib, a first-in-class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:AlexanianRaymondR,
pubmed-author:AlsinaMelissaM,
pubmed-author:AndersonKennethK,
pubmed-author:BarlogieBartB,
pubmed-author:BerensonJames RJR,
pubmed-author:EsseltineDixie LDL,
pubmed-author:IrwinDavidD,
pubmed-author:JagannathSundarS,
pubmed-author:LimentaniStevenS,
pubmed-author:NiesvizkyRubenR,
pubmed-author:RajkumarS VincentSV,
pubmed-author:RichardsonPaul GPG,
pubmed-author:SchenkeinDavid PDP,
pubmed-author:SiegelDavid TDT,
pubmed-author:SinghalSeemaS,
pubmed-author:SrkalovicGordonG,
pubmed-author:TrehuElizabethE
|
|
pubmed:copyrightInfo |
Copyright 2005 American Cancer Society
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
104
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2141-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16206291-Adult,
pubmed-meshheading:16206291-Aged,
pubmed-meshheading:16206291-Aged, 80 and over,
pubmed-meshheading:16206291-Anti-Inflammatory Agents,
pubmed-meshheading:16206291-Antineoplastic Agents,
pubmed-meshheading:16206291-Boronic Acids,
pubmed-meshheading:16206291-Dexamethasone,
pubmed-meshheading:16206291-Drug Resistance, Neoplasm,
pubmed-meshheading:16206291-Female,
pubmed-meshheading:16206291-Humans,
pubmed-meshheading:16206291-Male,
pubmed-meshheading:16206291-Middle Aged,
pubmed-meshheading:16206291-Multiple Myeloma,
pubmed-meshheading:16206291-Neoplasm Recurrence, Local,
pubmed-meshheading:16206291-Pyrazines,
pubmed-meshheading:16206291-Time Factors,
pubmed-meshheading:16206291-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
|
|
pubmed:affiliation |
Institute for Myeloma Bone Cancer Research, West Hollywood, California 90069, USA. jberenson@myelomasource.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
